Structure-Function Relationship between the Human Chemokine Receptor CXCR3 and Its Ligands*

I-TAC, IP10, and Mig are interferon-γ inducible CXC chemokines that share the same G-protein-coupled receptor CXCR3, which is preferentially expressed on Th1 lymphocytes. We have explored the structure-function relationship of the CXCR3 ligands, in particular of I-TAC, which has highest affinity for CXCR3 and is the most potent agonist. A potent antagonist for CXCR3 was obtained by NH2-terminal truncation of I-TAC. I-TAC (4–73), which lacks the first three residues, has no agonistic activity but competes for the binding of I-TAC to CXCR3-bearing cells and inhibits migration and Ca2+ changes in such cells in response to stimulation with I-TAC, IP10, and Mig. It does also not induce internalization of CXCR3, which is in support of the lack of agonistic effects. Hybrid chemokines between I-TAC and IP10 were used to identify regions responsible for the higher activity of I-TAC. I-TAC-like IP10 analogs are obtained by substituting the NH2 terminus (residues 1–8) or N-loop region (residues 12–17) of IP10 with those of I-TAC, suggesting that the differences in function of the CXCR3 ligands can be assigned to distinct regions and that these regions are interchangeable. Structure-activity studies with Mig showed that the extended basic COOH-terminal region, which is not present in I-TAC and IP10, is important for binding and activity.

[1]  B. Sykes,et al.  Solution structure and basis for functional activity of stromal cell‐derived factor‐1; dissociation of CXCR4 activation from binding and inhibition of HIV‐1 , 1997, The EMBO journal.

[2]  B. Sykes,et al.  Structure‐activity relationships of chemokines , 1995, Journal of leukocyte biology.

[3]  D. Jarrossay,et al.  Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon , 1999, Nature Medicine.

[4]  A. Gottlieb,et al.  Detection of a gamma interferon-induced protein IP-10 in psoriatic plaques , 1988, The Journal of experimental medicine.

[5]  M. Baggiolini,et al.  Structure-activity relationships of interleukin-8 determined using chemically synthesized analogs. Critical role of NH2-terminal residues and evidence for uncoupling of neutrophil chemotaxis, exocytosis, and receptor binding activities. , 1991, The Journal of biological chemistry.

[6]  M. Baggiolini,et al.  The Ligands of CXC Chemokine Receptor 3, I-TAC, Mig, and IP10, Are Natural Antagonists for CCR3* , 2001, The Journal of Biological Chemistry.

[7]  P. Murphy International Union of Pharmacology. XXX. Update on Chemokine Receptor Nomenclature , 2002, Pharmacological Reviews.

[8]  E Lazzeri,et al.  Interferon-inducible protein 10, monokine induced by interferon gamma, and interferon-inducible T-cell alpha chemoattractant are produced by thymic epithelial cells and attract T-cell receptor (TCR) alphabeta+ CD8+ single-positive T cells, TCRgammadelta+ T cells, and natural killer-type cells in hum , 2001, Blood.

[9]  L. Trentin,et al.  The chemokine receptor CXCR3 is expressed on malignant B cells and mediates chemotaxis. , 1999, The Journal of clinical investigation.

[10]  Bernhard Moser,et al.  Lymphocyte traffic control by chemokines , 2001, Nature Immunology.

[11]  R. Doms,et al.  CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. , 1999 .

[12]  B. Dewald,et al.  RANTES and MCP-3 Antagonists Bind Multiple Chemokine Receptors (*) , 1996, The Journal of Biological Chemistry.

[13]  B. Lindner,et al.  Dipeptidyl peptidase IV (CD26) on T cells cleaves the CXC chemokine CXCL11 (I‐TAC) and abolishes the stimulating but not the desensitizing potential of the chemokine , 2002, Journal of leukocyte biology.

[14]  H. Weiner,et al.  CCR5(+) and CXCR3(+) T cells are increased in multiple sclerosis and their ligands MIP-1alpha and IP-10 are expressed in demyelinating brain lesions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[15]  D. Patel,et al.  CXCR3 and CCR5 ligands in rheumatoid arthritis synovium. , 2001, Clinical immunology.

[16]  M. Baggiolini,et al.  HIV blocked by chemokine antagonist , 1996, Nature.

[17]  Simon A. Jones,et al.  Chemokine Antagonists That Discriminate between Interleukin-8 Receptors , 1997, The Journal of Biological Chemistry.

[18]  B. Sykes,et al.  The CXCR3 binding chemokine IP-10/CXCL10: structure and receptor interactions. , 2002, Biochemistry.

[19]  D. Dorfman,et al.  The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia. , 2000, Blood.

[20]  A. Zlotnik,et al.  Chemokines: a new classification system and their role in immunity. , 2000, Immunity.

[21]  P. Loetscher,et al.  Agonistic and antagonistic activities of chemokines , 2001, Journal of leukocyte biology.

[22]  Brian A. Hemmings,et al.  G-Protein-coupled Receptors and Fcγ-receptors Mediate Activation of Akt/Protein Kinase B in Human Phagocytes* , 1997, The Journal of Biological Chemistry.

[23]  C. Mackay,et al.  The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. , 1998, The Journal of clinical investigation.

[24]  M. Chilosi,et al.  Involvement of the IP-10 chemokine in sarcoid granulomatous reactions. , 1998, Journal of immunology.

[25]  O. Nishimura,et al.  A small-molecule, nonpeptide CCR5 antagonist with highly potent and selective anti-HIV-1 activity. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. Peck,et al.  A Small Molecule Antagonist of Chemokine Receptors CCR1 and CCR3 , 2000, The Journal of Biological Chemistry.

[27]  M. Baggiolini,et al.  Interleukin-2 regulates CC chemokine receptor expression and chemotactic responsiveness in T lymphocytes , 1996, The Journal of experimental medicine.

[28]  Elias Lolis,et al.  Structure, function, and inhibition of chemokines. , 2002, Annual review of pharmacology and toxicology.

[29]  B Dewald,et al.  Human chemokines: an update. , 1997, Annual review of immunology.

[30]  B. Dewald,et al.  N-terminal Peptides of Stromal Cell-derived Factor-1 with CXC Chemokine Receptor 4 Agonist and Antagonist Activities* , 1998, The Journal of Biological Chemistry.

[31]  Juan Pablo Albar,et al.  CXCR3 Chemokine Receptor Distribution in Normal and Inflamed Tissues: Expression on Activated Lymphocytes, Endothelial Cells, and Dendritic Cells , 2001, Laboratory Investigation.

[32]  E. Hudson,et al.  Differential expression and responsiveness of chemokine receptors (CXCR1–3) by human microvascular endothelial cells and umbilical vein endothelial cells , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[33]  M. Baggiolini,et al.  Ion channels in human neutrophils activated by a rise in free cytosolic calcium concentration , 1986, Nature.

[34]  M. Baggiolini,et al.  Blocking Chemokine Receptors , 1997, The Journal of experimental medicine.

[35]  P. Loetscher,et al.  Lymphocyte‐specific chemokine receptor CXCR3: regulation, chemokine binding and gene localization , 1998, European journal of immunology.

[36]  Simon A. Jones,et al.  Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes , 1996, The Journal of experimental medicine.

[37]  Jean Salamero,et al.  HIV Coreceptor Downregulation as Antiviral Principle: SDF-1α–dependent Internalization of the Chemokine Receptor CXCR4 Contributes to Inhibition of HIV Replication , 1997, The Journal of experimental medicine.

[38]  R. Rabin,et al.  Chemokine receptor responses on T cells are achieved through regulation of both receptor expression and signaling. , 1999, Journal of immunology.

[39]  M. Serio,et al.  Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity. , 2001, The Journal of clinical investigation.

[40]  J. Anderson,et al.  Chemical synthesis, purification, and folding of C-X-C and C-C chemokines. , 1997, Methods in enzymology.

[41]  J. Ravetch,et al.  Biochemical characterization of a gamma interferon-inducible cytokine (IP-10) , 1987, The Journal of experimental medicine.

[42]  Jakob S. Jensen,et al.  Expression of specific chemokines and chemokine receptors in the central nervous system of multiple sclerosis patients. , 1999, The Journal of clinical investigation.

[43]  P. Libby,et al.  Differential expression of three T lymphocyte-activating CXC chemokines by human atheroma-associated cells. , 1999, The Journal of clinical investigation.

[44]  J. Michel,et al.  Smooth muscle cell modulation and cytokine overproduction in varicose veins. An in situ study , 2001, The Journal of pathology.

[45]  S. Narula,et al.  Human interferon-inducible 10-kDa protein and human interferon-inducible T cell alpha chemoattractant are allotopic ligands for human CXCR3: differential binding to receptor states. , 2001, Molecular pharmacology.

[46]  G. Werner-Felmayer,et al.  Processing of natural and recombinant CXCR3-targeting chemokines and implications for biological activity. , 2001, European journal of biochemistry.

[47]  M. Baggiolini,et al.  CCR5 is characteristic of Th1 lymphocytes , 1998, Nature.

[48]  E. De Clercq,et al.  CD26/dipeptidyl-peptidase IV down-regulates the eosinophil chemotactic potency, but not the anti-HIV activity of human eotaxin by affecting its interaction with CC chemokine receptor 3. , 1999, Journal of immunology.

[49]  W. Hancock,et al.  Requirement of the Chemokine Receptor CXCR3 for Acute Allograft Rejection , 2000, The Journal of experimental medicine.

[50]  James G. Boyd,et al.  Interferon–inducible T Cell Alpha Chemoattractant (I-TAC): A Novel Non-ELR CXC Chemokine with Potent Activity on Activated T Cells through Selective High Affinity Binding to CXCR3 , 1998, The Journal of experimental medicine.

[51]  M. Parmentier,et al.  Amino-terminal truncation of CXCR3 agonists impairs receptor signaling and lymphocyte chemotaxis, while preserving antiangiogenic properties. , 2001, Blood.

[52]  C. Mackay,et al.  T-cell function and migration. Two sides of the same coin. , 2000, The New England journal of medicine.

[53]  M. Mack,et al.  Aminooxypentane-RANTES Induces CCR5 Internalization but Inhibits Recycling: A Novel Inhibitory Mechanism of HIV Infectivity , 1998, The Journal of experimental medicine.

[54]  M. Baggiolini,et al.  Eotaxin is a natural antagonist for CCR2 and an agonist for CCR5. , 2001, Blood.

[55]  P. Allavena,et al.  Differential Expression of Chemokine Receptors and Chemotactic Responsiveness of Type 1 T Helper Cells (Th1s) and Th2s , 1998, The Journal of experimental medicine.

[56]  J. Farber HuMig: a new human member of the chemokine family of cytokines. , 1993, Biochemical and biophysical research communications.

[57]  J. Edwardson,et al.  Endocytosis and recycling of G protein-coupled receptors. , 1997, Trends in pharmacological sciences.

[58]  F. Spertini,et al.  CXCR3 Internalization Following T Cell-Endothelial Cell Contact: Preferential Role of IFN-Inducible T Cell α Chemoattractant (CXCL11)1 , 2001, The Journal of Immunology.

[59]  ANTAGONISTS OF MONOCYTE CHEMOATTRACTANT PROTEIN 1 IDENTIFIED BY MODIFICATION OF FUNCTIONALLY CRITICAL NH2-TERMINAL RESIDUES , 1995 .

[60]  A. Luster,et al.  Donor-Derived Ip-10 Initiates Development of Acute Allograft Rejection , 2001, The Journal of experimental medicine.

[61]  K. Matsushima,et al.  International union of pharmacology. XXII. Nomenclature for chemokine receptors. , 2000, Pharmacological reviews.

[62]  B. Dewald,et al.  Interleukin-8 antagonists generated by N-terminal modification. , 1993, The Journal of biological chemistry.

[63]  Robert J. Lefkowitz,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[64]  C. Mackay,et al.  Flexible Programs of Chemokine Receptor Expression on Human Polarized T Helper 1 and 2 Lymphocytes , 1998, The Journal of experimental medicine.

[65]  C. Mackay,et al.  The role of chemokine receptors in primary, effector, and memory immune responses. , 2000, Annual review of immunology.